ISSN: 2476-2024

Diagnostic Pathology: Open Access
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • Diagnos Pathol Open,
  • DOI: 10.4172/2476-2024.S10.1000001

Immunohistochemical Evaluation of 5-Hydroxymethylcytosine (5-hmC) in Breast Phyllodes Tumors

Jasmine Vickery1, Lisa Han1, Stephen Dzul2, Wei Zhang3, Zhou Zhang3, Razvan Lapadat1, Husain Sattar1, Jeffrey Mueller1, Thomas Krausz1 and Anna Biernacka1*
1Department of Pathology, University of Chicago, Chicago, IL, USA
2Department of Radiation Oncology, Wayne State University, Detroit, MI, USA
3Department of Preventive Medicine, Northwestern University, Chicago, IL, USA
*Corresponding Author : Anna Biernacka, Department of Pathology, University of Chicago, Chicago, IL, USA, Tel: 773-834-8068, Email: abiernacka@bsd.uchicago.edu

Received Date: Feb 17, 2022 / Accepted Date: Mar 07, 2022 / Published Date: Mar 14, 2022

Abstract

Phyllodes Tumors (PTs) pose a significant diagnostic challenge in breast pathology as histological criteria and cutoffs for grading are complex and arbitrary. Nevertheless, the clinical behavior of PTs varies widely and correlates, in part, with the histological grade. Methylation signatures have gained interest as diagnostic and prognostic tools in a variety of neoplasms. In particular, 5-hydroxymethylcytosine (5-hmC) has been found to be a useful biomarker. Herein, we assess 51 PTs of varying grades and 15 cellular fibroadenomas (cFAs) for stromal expression of 5-hmC by immunohistochemistry. We demonstrate that nuclear 5-hmC decreases as PT grade increases, correlating with histologic predictors of adverse behavior, while it shows comparable levels in benign PTs and cFAs. We identify thresholds at which reduced 5-hmC levels help to distinguish borderline and malignant PT from their benign counterparts. Our results indicate that 5-hmC may serve as a valuable adjunct in classifying PTs in diagnostically difficult cases.

Keywords: Breast; Phyllodes tumor; 5-hydroxymethylcytosine; Immunohistochemistry; Fibroepithelial lesion; Fibroadenoma; Methylation; Epigenetics

Citation: Vickery J, Han L, Dzul S, Zhang Z, Zhang Z (2022) Immunohistochemical Evaluation of 5-Hydroxymethylcytosine (5-hmC) in Breast Phyllodes Tumors. Diagnos Pathol Open S1:001. Doi: 10.4172/2476-2024.S10.1000001

Copyright: © 2022 Biernacka A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top